Pipeline BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication BioSpaceBioMarin's discontinued drug showed biomarker benefits in a Phase 3 study for ENPP1 deficiency but these failed to translate to clinical improvements.Rare DiseaseRead full story pharminent August 10, 2026 (Last updated: August 11, 2026) BioSpace BioMarin’s discontinued drug showed biomarker benefits in a Phase 3 study for ENPP1 deficiency but these failed to translate to clinical improvements. Rare Disease Read full story Post navigation Previous: Replimune Readies Launch of Newly Approved Melanoma Therapy TudriqevNext: Jazz Pharmaceuticals Acquires Actio Biosciences for $820M Upfront Related Stories Pipeline Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage fail pharminent August 25, 2026 Pipeline Chasing Dupixent, a biotech aims to make better antibody drugs for eczema pharminent August 11, 2026 Pipeline Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease pharminent August 11, 2026
